Pfizer 2023 outlook disappoints as Covid business drops off

PFIZER’S 2023 forecasts fell short of analysts’ expectations on precipitously declining demand for its blockbuster Covid vaccines and Paxlovid treatment.

The company is predicting 2023 adjusted earnings between US$3.25 and US$3.45 a share, well below analysts average estimate of US$4.31 a share. Revenue for the year will be in the range of US$67 billion to US$71 billion, Pfizer said in a statement. Analysts had expected US$71.7 billion.

Pfizer’s Covid-19 vaccine Comirnaty and virus pill Paxlovid have been transformative for the company, contributing more than half of the company’s US$100 billion in sales last year. The company has been messaging for months that it wouldn’t be able to keep the pace, sharing forecasts for growth outside of Covid. Still, the downturn in its Covid business was more stark than analysts had been expecting, putting pressure on the drugmaker to show other avenues for growth.

For 2023, Pfizer said it expects sales of around US$13.5 billion for Comirnaty, down 64 per cent from the year before and below the US$16 billion forecast by analysts. Its 2023 sales guidance for its Covid pill Paxlovid was US$8 billion, down 58 per cent from the year prior and below the US$9.2 billion expected by Wall Street.

Pfizer’s shares were down less than 1 per cent as of 9.58 am in New York. The American depositary receipts of its vaccine partner, Germany’s BioNTech were little changed. Rival Moderna fell 3.3 per cent.

For the fourth quarter, Pfizer’s adjusted profit was US$1.14 a share, beating analysts’ expectations for earnings of US$1.05. Sales were US$24.3 billion, in line with Wall Street’s expectations for US$24.2 billion.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL

Pfizer did say it expects its Covid business to grow again in 2024 after “reaching a low point in 2023” due to governments having substantial supply of the products already, thereby negating the need for further orders.

Pfizer’s expenses are expected to be far higher in 2023, said Bloomberg Intelligence analyst John Murphy. That’s due to spending on the launches of potential new products as well as the shift of its Covid products to the private insurance market in the US, he said. Those may end up being a worthwhile investments: “If they can use that big incremental expense to drive sustainable top-line growth around that level of 7 per cent to 9 per cent this year, then many would view that incremental spend as justified,” Murphy said.

For its part, Pfizer has been clear that it’s looking ahead to find growth post-Covid. Last year “was a record-breaking year for Pfizer”, chief executive officer Albert Bourla said in an earnings statement. “As proud as we are about what we have accomplished, our focus is always on what is next.” BLOOMBERG